Semaglutide · 3 min read
Nausea in ~44% of STEP 1 patients, mostly early and transient — plus the serious-but-rare tier, the boxed warning, the anesthesia rule, and the "Ozempic face" question answered honestly.
Nausea in ~44% of STEP 1 patients, mostly early and transient — plus the serious-but-rare tier, the boxed warning, the anesthesia rule, and the "Ozempic face" question answered honestly.
Semaglutide's side-effect ledger is long-studied and mostly gastrointestinal. In STEP 1, nausea affected about 44% of participants at some point across 68 weeks, diarrhea about 30%, vomiting and constipation each roughly a quarter — overwhelmingly mild-to-moderate, clustered around dose escalations, and fading at stable doses. About 7% discontinued for GI events. That is the common experience; the rare tier and the internet-famous tier both deserve straight answers.
The playbook mirrors the class: smaller and slower meals, stopping at satisfied (delayed gastric emptying makes overeating physically punishing), lighter fat on injection days, deliberate hydration, and a titration pace that respects symptoms — holding a dose is a tool, not a setback. Constipation wants fluid, fiber, and movement first. Heartburn and burping respond to meal timing and, when needed, a clinician conversation. Most of it is front-loaded: the sixteen-week climb is the hard part, maintenance is usually quieter.
The same five items as the rest of the class, with semaglutide's specifics. Pancreatitis — rare; severe persistent abdominal pain means stop and seek care. Gallbladder disease — cholelithiasis ran about 1.6% versus 1.1% placebo in STEP 1; biliary pain warrants evaluation. Dehydration and kidney injury from protracted vomiting or diarrhea. Ileus — added to postmarket labeling for this molecule specifically. Hypoglycemia — mainly in combination with insulin or sulfonylureas. Plus the class boxed warning (rodent thyroid C-cell tumors; contraindicated with personal or family MTC/MEN 2 history), pregnancy avoidance with a two-month washout recommendation before conception, the pre-procedure anesthesia disclosure rule, and a labeled note on gastroparesis-like presentations. Eye caution is semaglutide-specific: worsening of diabetic retinopathy occurred in some diabetes trials with rapid glucose improvement, and 2025-era case reports around NAION prompted label-level attention — established retinopathy or sudden visual change belongs in front of a clinician promptly.
Facial volume loss is not a drug toxicity; it is fat loss expressed where humans look at each other, proportional to speed and magnitude of weight loss, and identical in kind to what large dietary or surgical loss produces. Slower titration, adequate protein, and resistance training moderate it; the same goes for telogen-effluvium-style hair shedding, which typically follows any rapid loss and resolves as weight stabilizes. Our muscle-preservation guide covers the protein-and-training half of that answer.
Educational, not medical advice. Persistent or severe symptoms belong with your prescriber; serious events can be reported to FDA MedWatch.
Gastrointestinal: nausea (~44% in STEP 1 across 68 weeks), diarrhea (~30%), vomiting and constipation (~24% each) — mostly mild-to-moderate, worst around dose increases, improving at stable doses.
It carries a boxed warning based on C-cell tumors in rodents; human relevance is unestablished. It is contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2, and new neck symptoms warrant evaluation.
Tell every anesthesiologist and proceduralist you take it. Because it delays gastric emptying, perioperative guidance addresses holding GLP-1 drugs before sedation; the decision is made by your care team, not unilaterally.